Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 640 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Transfusion Clear all
Completed Phase 3 Interventional Results available

Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload

NCT00235391
View directory record Official record
Conditions
Thalassemia, Sickle Cell Disease, Diamond Blackfan Anemia, Myelofibrosis
Interventions
Deferasirox
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years and older
Enrollment
1,683 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
27
States / cities
Little Rock, Arkansas • Berkeley, California • Orange, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2011 · Synced Oct 22, 2026, 4:57 AM EDT
Completed Phase 3 Interventional Results available

A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS

NCT00656448
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Leukemia
Interventions
Procrit
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 30, 2018 · Synced Oct 22, 2026, 4:57 AM EDT
Completed Not applicable Interventional

Effects of a Platelet Transfusion Best Practices Alert

NCT04155775
View directory record Official record
Conditions
Thrombocytopenia
Interventions
Computer electronic health record alert (Best Practice Alert - BPA)
Other
Lead sponsor
Stanford University
Other
Eligibility
Not listed
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 22, 2026, 4:57 AM EDT
Completed No phase listed Observational

Measurements of Anemia and Physiologic Tissue Response to Blood Transfusions in VLBW Infants Using Quantitative NIRS

NCT00544375
View directory record Official record
Conditions
Infant Development
Interventions
Optical measurement
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
1 Minute to 1 Month
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Oct 22, 2026, 4:57 AM EDT
Completed Phase 2 Interventional Results available

Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)

NCT02515630
View directory record Official record
Conditions
Primary Myelofibrosis (PMF), Post-polycythemia Vera (Post-PV) Myelofibrosis, Postessential Thrombocythemia (Post-ET) Myelofibrosis
Interventions
MMB
Drug
Lead sponsor
Sierra Oncology LLC - a GSK company
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angeles, California • Orange, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 22, 2026, 4:57 AM EDT
Completed Phase 3 Interventional Results available

Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy

NCT01103323
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Regorafenib (Stivarga, BAY73-4506), Placebo, Best Supportive Care (BSC)
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
760 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
26
States / cities
Beverly Hills, California • Los Angeles, California • Mission Hills, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2015 · Synced Oct 22, 2026, 4:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Blood Transfusion in Healthy Volunteers

NCT01226498
View directory record Official record
Conditions
Blood Transfusion, Autologous
Interventions
Red blood Cells auto-transfusion
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 40 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 30, 2014 · Synced Oct 22, 2026, 4:57 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Effects of Transfusion of Older Stored Red Cells

NCT01534676
View directory record Official record
Conditions
Sickle Cell Disease, Thalassemia
Interventions
Transfusion, Blood, Chelation therapy
Procedure · Biological
Lead sponsor
Columbia University
Other
Eligibility
1 Year to 65 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 5, 2016 · Synced Oct 22, 2026, 4:57 AM EDT
Completed Phase 2 Interventional

New Therapeutic Strategies for Patients With Ewing's Sarcoma Family of Tumors, High Risk Rhabdomyosarcoma, and Neuroblastoma

NCT00001335
View directory record Official record
Conditions
Ewing's Sarcoma, Neuroblastoma, Rhabdomyosarcoma
Interventions
ADR-529, Topotecan, G-CSF
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 22, 2026, 4:57 AM EDT
Terminated Phase 2 Interventional Results available

Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer

NCT00932152
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Postmenopausal Women
Interventions
fulvestrant (Faslodex), anastrozole (Arimidex), Bevacizumab (Avastin), Best supportive care
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 19, 2017 · Synced Oct 22, 2026, 4:57 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia

NCT00037791
View directory record Official record
Conditions
Neoplasms, Thrombocytopenia, Multiple Myeloma, Lymphoma, Malignant
Interventions
(PN-152,243)/PN-196,444
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
6
States / cities
Berkeley, California • La Jolla, California • Los Angeles, California + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2006 · Synced Oct 22, 2026, 4:57 AM EDT
Completed Not applicable Interventional

Combining Restrictive Guidelines and a NIRS SCORE to Decrease RBC Transfusions

NCT02535208
View directory record Official record
Conditions
Anemia of Prematurity (AOP)
Interventions
Restrictive transfusions based on SCOR assessment, Liberal transfusions
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
Up to 3 Days
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 19, 2018 · Synced Oct 22, 2026, 4:57 AM EDT
Completed Not applicable Interventional Results available

TXA Study in Major Oncologic Surgery

NCT01980355
View directory record Official record
Conditions
Tranexamic Acid, Cancer, Major Surgery
Interventions
Tranexamic Acid, Placebo
Drug · Other
Lead sponsor
Corewell Health West
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 7, 2023 · Synced Oct 22, 2026, 4:57 AM EDT
Active, not recruiting Not applicable Interventional

Trial of Indication-Based Transfusion of Red Blood Cells in ECMO

NCT05405426
View directory record Official record
Conditions
Extracorporeal Membrane Oxygenation, Red Blood Cell Transfusion, Organ Failure, Multiple
Interventions
Red blood cell transfusion
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
0 Days to 6 Years
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
20
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 22, 2026, 4:57 AM EDT
Active, not recruiting Phase 3 Interventional

The HeLiX (Hemorrhage During Liver Resection: traneXamic Acid) Trial

NCT02261415
View directory record Official record
Conditions
Cancer, Tumour, Surgery
Interventions
Tranexamic acid (TXA), Normal saline
Drug
Lead sponsor
Sunnybrook Health Sciences Centre
Other
Eligibility
18 Years and older
Enrollment
1,386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Oct 22, 2026, 4:57 AM EDT
Withdrawn Phase 4 Interventional

Single Versus Multi-Dose Oral Tranexamic Acid in Patients at High Risk for Blood Transfusion After Total Joint Arthroplasty

NCT02926651
View directory record Official record
Conditions
Anemia, Arthritis, Total Knee Arthroplasty, Total Hip Arthroplasty
Interventions
Conventional Oral TXA (Tranexamic Acid), Multi-Dose Oral TXA (Tranexamic Acid)
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Oct 22, 2026, 4:57 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Age of Blood in Sickle Cell Transfusion

NCT03704922
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Transfusion
Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 60 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
3
States / cities
Atlanta, Georgia • Chapel Hill, North Carolina • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 22, 2026, 4:57 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Luspatercept + Darbepoetin in MDS

NCT07096297
View directory record Official record
Conditions
MDS (Myelodysplastic Syndrome)
Interventions
Luspatercept, Darbeopoetin
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
4
States / cities
New Haven, Connecticut • Chicago, Illinois • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 22, 2026, 4:57 AM EDT
Completed Not applicable Interventional Results available

Peri-Transfusion QOL Assessments (PTQA): A New Paradigm of Transfusion Decision Support for Patients With MDS

NCT03660228
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Peri-Transfusion QOL Assessment
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 21, 2024 · Synced Oct 22, 2026, 4:57 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Changes in Pituitary Iron and Volume With Deferasirox

NCT01376622
View directory record Official record
Conditions
Iron Overload
Interventions
Not listed
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
2 Years to 25 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2023 · Synced Oct 22, 2026, 4:57 AM EDT
Completed No phase listed Observational

Effects of Antibodies to White Blood Cells on Platelet Transfusion Patients

NCT00460122
View directory record Official record
Conditions
Healthy, Transfusion Reactions
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Oct 22, 2026, 4:57 AM EDT
Completed Not applicable Interventional

SAHaRA: A Randomized Controlled Trial

NCT03309579
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Aneurysmal
Interventions
Liberal RBC Transfusion Strategy, Restrictive RBC Transfusion Strategy
Other
Lead sponsor
Ottawa Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
742 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
3
States / cities
Aurora, Colorado • Atlanta, Georgia • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 6, 2024 · Synced Oct 22, 2026, 4:57 AM EDT
Terminated Phase 2 Interventional Results available

BMT and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance

NCT02029638
View directory record Official record
Conditions
Kidney Transplantation
Interventions
anti-thymocyte globulin, Fludarabine, Cyclophosphamide, Total Body Irradiation, acetaminophen, diphenhydramine, methylprednisolone, bone marrow transplant, MESNA, mycophenolate mofetil, prednisone, filgrastim
Biological · Drug · Radiation
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced Oct 22, 2026, 4:57 AM EDT
Withdrawn Not applicable Interventional

Study of Platelet Rich Plasma Drops to Moderate Clinically Significant Dry Eye

NCT05121493
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Platelet Poor Plasma Tear Drops, Platelet Rich Plasma Tear Drops
Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 22, 2026, 4:57 AM EDT